BMBF awards research grant to Scil Technology
Scil Technology, a company engaged in drug development, formulation and analytics, is a wholly owned subsidiary of BioNet Holding. Scil Technology CEO Christian Nafe said the grant will
China-based IMPACT Therapeutics and Pharmanovia have entered an exclusive licensing deal worth up to €423.5m ($488.3m), giving Pharmanovia rights to manufacture, develop, and commercialise senaparib in 66 countries.